Cisplatin: Continuous versus bolus

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 2, 2006, Pages 60-61

  Gratton, Michael Anne ^a   Smyth, Brendan J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CISPLATIN; LOOP DIURETIC AGENT;

ANTINEOPLASTIC ACTIVITY; CHILDHOOD CANCER; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; NEPHROTOXICITY; NOTE; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; CHILD; CISPLATIN; ENDODERMAL SINUS TUMOR; HALF-LIFE; HEARING LOSS, SENSORINEURAL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; NEOPLASMS, GERM CELL AND EMBRYONAL; PROTEIN BINDING; RETROSPECTIVE STUDIES;

EID: 33644617235     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000199584.91302.e5     Document Type: Note

References (19)

1. Einhorn L, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87:293-298.
2. Reddy AT, Witek K. Neurologic complications of chemotherapy for children with cancer. Curr Neurol Neurosci Rep. 2003;3:137-142.
3. de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88:1199-1206.
4. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355-1362.
5. Blakley BW, Gupta AK, Myers SF, et al. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994;120:541-546.
6. Gratton MA, Salvi RJ, Kamen BA, et al. Interaction of cisplatin and noise on the peripheral auditory system. Hear Res. 1990;50:211-223.
7. Gratton MA, Smyth BJ. Platinum compounds. In: Roland P, Rutka J, eds. Ototoxicity. Hamilton, Ontario: BC Decker Inc., 2005;60-75.
8. Rosenberg B. Fundamental studies with cisplatin. Cancer. 1984;55:2303-2316.
9. Skinner R, Pearson AD, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927-931.
10. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000;18:3819-3828.
11. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295-309.
12. Dominici C, Petrucci F, Caroli S, et al. A pharmacokinetic study of high-dose continuous infusion cisplatin children with solid tumors. J Clin Oncol. 1989;7:100-107.
13. Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823-1828.
14. De Conti RC, Toftness BR, Lange RC, et al. Clinical and pharmacological studies with cis-dichlorodiammineplatinum (II). Cancer Res. 1973;33:1310-1315.
15. Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet. 1987;12:168-213.
16. Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther. 1990;6:145-151.
17. Forastiere AA, Belliveau JF, Goren MP, et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res. 1988;48:3869-3874.
18. Reddel RR, Kefford RF, Grant JM, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982;66:19-23.
19. Erdlenbruch B, Pekrum A, Roth C, et al. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol. 2001;16:586-593.